Clinical Trials
14 trialsNCT03583528 2026-05-12
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Active not recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT04706910 2026-02-09
18F-DOPA II - PET Imaging Optimization
University of Alberta
Phase 3 Recruiting
NCT05069220 2024-03-01
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT03273712 2023-02-09
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
Phase 2 Completed
NCT03042416 2022-01-10
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
University of Alberta
Phase 3 Completed
NCT01869725 2021-09-22
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Phase 2 Completed
NCT01619865 2021-07-27
GA-68
University of Iowa
Phase 1/2 Completed
NCT04017104 2021-01-26
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
British Columbia Cancer Agency
Unknown
NCT02441062 2020-12-21
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
University of Iowa
Phase 2 Completed
NCT02177773 2019-11-12
DOTA-TOC
University of California, San Francisco
Phase 1/2 Terminated
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT01048086 2016-06-21
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
University of Iowa
Phase 2 Withdrawn